iBio, Inc. stock is up 12.17% since 30 days ago. The next earnings date is May 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 13 February’s closed higher than January.
iBio, Inc. provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!